Skip to main content
. 2021 Sep 24;39(44):6520–6528. doi: 10.1016/j.vaccine.2021.09.052

Table 2.

Treatment Compliance in Immunogenicity Subset Group.

Vaccine
n (%)
Placebo
n (%)
Total
N (%)
Subjects screened for RT-PCR test 405 135 540
Subjects screened for IgM/IgG test 405 135 540
Subjects enrolled 405 135 540
First vaccination completed 405 135 540
Second vaccination completed 397 133 530
Intention-to-treat population (for safety and efficacy analysis) 405 135 540
Per-protocol population (for immunogenicity analysis 14 days after last injection) 397 133 530